Neovasc Sees Opportunities In Refractory Angina And Mitral Regurgitation Markets
Executive Summary
Neovasc Inc. is targeting two highly underserved markets in cardiology – refractory angina and mitral valve disease – with unique transcatheter solutions. The angina device, called the Neovasc Reducer, is expected to enter the European market early next year.